SAFETY AND EFFICACY OF INSULIN GLARGINE/LIXISENATIDE AND INSULIN DEGLUDEC/INSULIN ASPART IN TYPE 2 DIABETES PATIENTS NOT CONTROLLED ON BASAL INSULIN: A NETWORK META-ANALYSIS

被引：0
|
作者：
Jammah, A. [1 ]
机构：
[1] King Saud Univ, Dept Endocrinol, Riyadh, Saudi Arabia
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
394
引用
收藏
页码：A185 / A186
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both with insulin degludec with or without metformin, in adults with type 2 diabetes
    Lane, W.
    Bozkurt, K.
    Favaro, E.
    Jang, H. C.
    Kjaersgaard, M. I. S.
    Oviedo, A.
    Rose, L.
    Senior, P.
    Sesti, G.
    Soto Gonzalez, A.
    Franek, E.
    DIABETOLOGIA, 2019, 62 : S10 - S11
  • [32] Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus: Using insulin glargine as basal insulin
    Kawamori, Ryuzo
    Kadowaki, Takashi
    Ishii, Hitoshi
    Iwasaki, Manabu
    Iwamoto, Yasuhiko
    DIABETES, 2008, 57 : A573 - A573
  • [33] Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes
    Gunes, E.
    Gunes, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (14) : 6691 - 6699
  • [34] Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp) vs. Insulin Glargine (IGlarU300) in Insulin-Naïve Patients with Type 2 Diabetes: A Retrospective Study
    Hasnani, Dhruvi
    Jha, Santosh
    Saboo, Banshi
    Prasanna, Pusala Lakshmi
    Sanghvi, Ami
    Sowani, Alpana
    Chavda, Vipul
    CLINICAL DIABETOLOGY, 2024, 13 (01): : 67 - 75
  • [35] Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naive Japanese adults with type 2 diabetes: a pilot, randomized, controlled study
    Shimoda, Seiya
    Sakamoto, Wakana
    Hokamura, Ayaka
    Matsuo, Yasuto
    Sekigami, Taiji
    Ichimori, Shinji
    Iwashita, Shinsuke
    Ishii, Norio
    Otsu, Kae
    Yoshimura, Ryohei
    Nishiyama, Toshihiko
    Sakaguchi, Masaji
    Nishida, Kcnro
    Araki, Eiichi
    ENDOCRINE JOURNAL, 2019, 66 (08) : 745 - 752
  • [36] Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
    Liu, Wei
    Yang, Xiaojie
    Huang, Jing
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2018, 2018
  • [37] Reduced risk of hypoglycaemia with insulin degludec vs insulin glargine in patients with Type 2 diabetes requiring high dose basal insulin
    Gough, S.
    Rodbard, H.
    Handelsman, Y.
    Dykiel, P.
    Lassota, N.
    Lane, W.
    DIABETIC MEDICINE, 2013, 30 : 55 - 55
  • [38] REDUCED RISK OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES REQUIRING HIGH DOSES OF BASAL INSULIN: A META-ANALYSIS OF 5 RANDOMIZED BEGIN TRIALS
    Rodbard, Helena W.
    Gough, Stephen
    Lane, Wendy
    Korsholm, Lars
    Bretler, Ditte-Marie
    Handelsman, Yehuda
    ENDOCRINE PRACTICE, 2014, 20 (04) : 285 - 292
  • [39] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [40] Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes
    Urakami, Tatsuhiko
    Kuwabara, Remi
    Aoki, Masako
    Okuno, Misako
    Suzuki, Junichi
    ENDOCRINE JOURNAL, 2016, 63 (02) : 159 - 167
12345